市場調查報告書
商品編碼
966814

復發性/難治性何杰金氏淋巴瘤 (R/R HL) :流行病學考察 (∼2030年)

Relapsed/Refractory Hodgkin Lymphoma (R/R HL) - Epidemiology Insight - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供美國,歐洲5國(德國,西班牙,義大利,法國,英國)以及日本等7個主要市場復發性/難治性何杰金氏淋巴瘤 (R/R 在HL) 市場相關詳細說明,提供疾病的背景和概要,未滿足需求,各國的流行病學,治療方法等相關資訊。

目錄

第1章 主要考察

第2章 摘要整理

第3章 復發性/難治性何杰金氏淋巴瘤 (R/R HL) :疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第4章 患者治療過程

第5章 流行病學和患者人口

  • 流行病學的主要調查結果
  • 前提條件與理論的根據:主要7個國家
  • 流行病學方案:主要7個國家
    • 主要7個國家的復發性/難治性何杰金氏淋巴瘤 (R/R 主要7個國家HL)的流行病學方案
  • 美國的流行病學
    • 美國的復發性/難治性何杰金氏淋巴瘤 (R/R HL)的流行病學方案
  • 歐洲5國的流行病學:各國
    • 德國的流行病學
    • 法國的流行病學
    • 義大利的流行病學
    • 西班牙的流行病學
    • 英國的流行病學
  • 日本的流行病學
    • 日本的復發性/難治性何杰金氏淋巴瘤 (R/R HL)的流行病學方案

第6章 治療流程,目前治療,及醫療行為

  • 復發性/難治性何杰金氏淋巴瘤 (R/R 與HL)的治療管理
  • 復發性/難治性何杰金氏淋巴瘤 (R/R HL)的治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

  • 參考文獻
  • 報告的調查手法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1089

DelveInsight's 'Relapsed/Refractory Hodgkin Lymphoma (R/R HL) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Understanding

The DelveInsight Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology report gives a thorough understanding of the Relapsed/Refractory Hodgkin Lymphoma (R/R HL) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Relapsed/Refractory Hodgkin Lymphoma (R/R HL) in the US, Europe, and Japan. The report covers the detailed information of the Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology scenario in seven major countries (US, EU5, and Japan).

Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Perspective by DelveInsight

The Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Detailed Epidemiology Segmentation

The Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology covered in the report provides historical as well as forecasted Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Relapsed/Refractory Hodgkin Lymphoma (R/R HL) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Relapsed/Refractory Hodgkin Lymphoma (R/R HL) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Report and Model provide an overview of the risk factors and global trends of Relapsed/Refractory Hodgkin Lymphoma (R/R HL) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Relapsed/Refractory Hodgkin Lymphoma (R/R HL) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Relapsed/Refractory Hodgkin Lymphoma (R/R HL)
  • The report provides the segmentation of the Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology

Report Highlights:

  • 11-Year Forecast of Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology
  • 7MM Coverage
  • Total Cases of Relapsed/Refractory Hodgkin Lymphoma (R/R HL)
  • Total Cases of Relapsed/Refractory Hodgkin Lymphoma (R/R HL) according to segmentation
  • Diagnosed cases of Relapsed/Refractory Hodgkin Lymphoma (R/R HL)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Relapsed/Refractory Hodgkin Lymphoma (R/R HL) ?
  • What are the key findings pertaining to the Relapsed/Refractory Hodgkin Lymphoma (R/R HL) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Relapsed/Refractory Hodgkin Lymphoma (R/R HL) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Relapsed/Refractory Hodgkin Lymphoma (R/R HL) ?
  • What are the currently available treatments of Relapsed/Refractory Hodgkin Lymphoma (R/R HL) ?

Reasons to buy:

  • The Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Relapsed/Refractory Hodgkin Lymphoma (R/R HL) market
  • Quantify patient populations in the global Relapsed/Refractory Hodgkin Lymphoma (R/R HL) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Relapsed/Refractory Hodgkin Lymphoma (R/R HL) therapeutics in each of the markets covered
  • Understand the magnitude of Relapsed/Refractory Hodgkin Lymphoma (R/R HL) population by its epidemiology
  • The Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Relapsed/Refractory Hodgkin Lymphoma (R/R HL)

3. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Treatment and Management
  • 6.2. Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in 7MM (2017-2030)
  • Table 2: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in the United States (2017-2030)
  • Table 4: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in Germany (2017-2030)
  • Table 6: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in France (2017-2030)
  • Table 8: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in Italy (2017-2030)
  • Table 10: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in Spain (2017-2030)
  • Table 12: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in Japan (2017-2030)
  • Table 16: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in 7MM (2017-2030)
  • Figure 2: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in the United States (2017-2030)
  • Figure 4: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in Germany (2017-2030)
  • Figure 6: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in France (2017-2030)
  • Figure 8: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in Italy (2017-2030)
  • Figure 10: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in Spain (2017-2030)
  • Figure 12: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Epidemiology in Japan (2017-2030)
  • Figure 16: Relapsed/Refractory Hodgkin Lymphoma (R/R HL) Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report